

**Discloser Identifier:** 1060479

**Disclosure Purpose:** 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Additional Information: Full-time employee, own stock		<i>Position Description:</i>

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. Are you the corresponding author?

Yes.

a. Please list the other authors' names here.

Chalkias, Spyros; Feng, Jing; Chen, Xing; Zhou, Honghong; Marshall, Jean-Claude; Girard, Bethany; Tomassini, Joanne; Kuter, Barbara; Montefiori, David; Das, Rituparna

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Xing Chen

Discloser Identifier: 1085658

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i> Biostatistics
Moderna	Stock	Self
<i>Additional Information:</i>		
Moderna	Stock Option	Self
<i>Additional Information:</i>		

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1060578

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
ModernaTherapeutics	Employment	Self
<i>Title:</i> VP of Clinical Development <i>Additional Information:</i>		<i>Position Description:</i>

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Jingyuan Feng

Discloser Identifier: 1060480

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i>
Moderna	Stock	Self
<i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Bethany Girard

Discloser Identifier: 1026902

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna Therapeutics	Employment	Self
<i>Title:</i> Associate Director - Clinical Biomarkers <i>Additional Information:</i>		<i>Position Description:</i>

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Barbara Kuter

Discloser Identifier: 1088902

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Merck	Other	Self
<i>Category:</i> Other <i>Description:</i> Former employee of Merck <i>Additional Information:</i> Ended employment at Merck in Jan 2020		
Moderna	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> <i>Additional Information:</i>		

## Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. **Are you the corresponding author?**

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

# Jean-Claude Marshall

Discloser Identifier: 1091575

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Head of Clinical Biomarkers <i>Additional Information:</i>		<i>Position Description:</i> Head of clinical biomarkers for Moderna
Moderna	Stock	Self
<i>Additional Information:</i>		

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 590828

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna	Grant / Contract	Self
<i>Recipient Name:</i> David C. Montefiori <i>Recipient Type:</i> Institution <i>Grant / Contract Description:</i> Funding for neutralization assays on clinical samples from Moderna COVID-19 vaccine recipients <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>		
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> David C. Montefiori <i>Recipient Type:</i> Institution <i>Grant / Contract Description:</i> NIH 75N93019C00050 <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>		
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> David C. Montefiori <i>Recipient Type:</i> Institution <i>Grant / Contract Description:</i> NIH 75N93019C00050 Funding to support neutralization assays with SARS-CoV-2 variants <i>Grant / Contract Purpose:</i> Research <i>Additional Information:</i>		

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.





Joanne Tomassini

Discloser Identifier: 1040406

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna, Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Infectious diseases consultant <i>Additional Information:</i>		

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 969787

Disclosure Purpose: 22-12772

## Summary of Interests

### Company or Organization

Entity	Type	Interest Held By
Moderna	Employment	Self
<i>Title:</i> Sr. Director <i>Additional Information:</i>		<i>Position Description:</i> Biostatistics
Moderna	Stock	Self
<i>Additional Information:</i> As an employee of Moderna, i am also a stock holder of Moderna stock		

## Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Neutralization of Omicron BA.2.75 after Bivalent Vaccination

3. Are you the corresponding author?

No.

## Certification

I certify that the information provided in this disclosure is complete and accurate.